https://scholars.lib.ntu.edu.tw/handle/123456789/495033
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Ghamande S. | en_US |
dc.contributor.author | CHIA-CHI LIN | en_US |
dc.contributor.author | Cho D.C. | en_US |
dc.contributor.author | Shapiro G.I. | en_US |
dc.contributor.author | Kwak E.L. | en_US |
dc.contributor.author | Silverman M.H. | en_US |
dc.contributor.author | Tseng Y. | en_US |
dc.contributor.author | Kuo M.-W. | en_US |
dc.contributor.author | Mach W.B. | en_US |
dc.contributor.author | Hsu S.-C. | en_US |
dc.contributor.author | Coleman T. | en_US |
dc.contributor.author | CHIH-HSIN YANG | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.contributor.author | Ghalib M.H. | en_US |
dc.contributor.author | Chuadhary I. | en_US |
dc.contributor.author | Goel S. | en_US |
dc.creator | Ghamande S;Lin C.-C;Cho D.C;Shapiro G.I;Kwak E.L;Silverman M.H;Tseng Y;Kuo M.-W;Mach W.B;Hsu S.-C;Coleman T;Chih-Hsin Yang;Cheng A.-L;Ghalib M.H;Chuadhary I;Goel S. | - |
dc.date.accessioned | 2020-05-26T09:27:00Z | - |
dc.date.available | 2020-05-26T09:27:00Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0167-6997 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84904639018&doi=10.1007%2fs10637-013-0044-7&partnerID=40&md5=dcc564ea9ee9f962a7b1da02c0fb4411 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/495033 | - |
dc.description.abstract | Purpose: The first-in-human phase 1 trial examined the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), pharmacokinetic profile, and antitumor activity of TLC388, a novel camptothecin with a unique lactone ring modification, in patients with advanced solid tumors. Experimental design: TLC388 was administered intravenously to patients with metastatic chemotherapy refractory solid tumors on days 1, 8, and 15 of a 28-day cycle. Patients underwent tumor assessments every other cycle. Pharmacokinetic samples were drawn on days 1, 8, and 15 of cycles 1 and 2. Results: Fifty-four patients were enrolled at doses ranging from 1.5 to 60.0 mg/m2 over 12 cohorts. Treatment was generally well-tolerated and no cumulative toxicity observed. Two of six patients treated at 60.0 mg/m2 developed DLTs of grade 3 neutropenia causing dose delay and grade 3 febrile neutropenia. The next lower dose, 50.0 mg/m2, was declared as MTD. Treatment-related grade 3-4 hematologic toxicities included neutropenia (19 %), leukopenia (15 %), anemia (9 %), and thrombocytopenia (7 %). Grade 3-4 nonhematologic toxicities included diarrhea (2 %) and hyponatremia (4 %). Pharmacokinetics of both diastereomers (S,R and S,S) of TLC388, a mixture of two diastereomers, was dose independent; mean (SD) values for the volume of distribution at steady-state and clearance were 857 (1122) L/m2 for S,R and 996 (1333) L/m2 for S,S, and 2174 (2526) L/h-m2 for S,R and 2670 (2988) L/h-m2 for S,S, respectively. The half-life values averaged 0.67 (1.15) hours for S,R and 0.64 (1.11) hours for S,S. The best overall response was stable disease in 21 (39 %) patients. Prolonged (? 6 months) stable disease was noted in eight patients. Conclusions: TLC388 at 50 mg/m2 on the current treatment schedule is generally safe and well tolerated. ? 2013 Springer Science+Business Media. | - |
dc.publisher | Springer New York LLC | - |
dc.relation.ispartof | Investigational New Drugs | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | alanine aminotransferase; aspartate aminotransferase; camptothecin; tlc 388; unclassified drug; antineoplastic agent; camptothecin; TLC 388; adult; advanced cancer; aged; alanine aminotransferase blood level; anemia; antineoplastic activity; area under the curve; article; aspartate aminotransferase blood level; bile duct carcinoma; cardiopulmonary insufficiency; cerebrovascular accident; cohort analysis; colon tumor; constipation; diarrhea; dose limiting toxicity; drug clearance; drug distribution; drug dose escalation; drug dose reduction; drug half life; drug safety; drug structure; drug tolerability; drug withdrawal; esophagus tumor; fatigue; febrile neutropenia; female; human; hyperbilirubinemia; hyponatremia; kidney carcinoma; leukopenia; major clinical study; male; maximum plasma concentration; maximum tolerated dose; multiple cycle treatment; nausea; neutropenia; open study; pancreas tumor; phase 1 clinical trial; pleura effusion; priority journal; prostate tumor; solid tumor; thrombocytopenia; time to maximum plasma concentration; toxicological parameters; transitional cell carcinoma; urinary tract infection; uterine cervix tumor; vomiting; analogs and derivatives; blood; chemically induced; clinical trial; leukopenia; middle aged; multicenter study; Neoplasms; thrombocytopenia; urine; very elderly; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Thrombocytopenia | - |
dc.title | A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1007/s10637-013-0044-7 | - |
dc.identifier.pmid | 24271274 | - |
dc.identifier.scopus | 2-s2.0-84904639018 | - |
dc.relation.pages | 445-451 | - |
dc.relation.journalvolume | 32 | - |
dc.relation.journalissue | 3 | - |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.dept | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.orcid | 0000-0002-5586-5138 | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。